Impact of the amount of preoperative erector spinae muscle in stage I non-small-cell lung cancer

被引:6
|
作者
Ueda, Daisuke [1 ]
Tsutani, Yasuhiro [1 ]
Kamigaichi, Atsushi [1 ]
Kawamoto, Nobutaka [1 ]
Tsubokawa, Norifumi [1 ]
Ito, Masaoki [1 ]
Mimae, Takahiro [1 ]
Miyata, Yoshihiro [1 ]
Okada, Morihito [1 ,2 ]
机构
[1] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, Hiroshima, Japan
[2] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, 1-2-3 Kasumi,Minami ku, Hiroshima, Hiroshima 7348551, Japan
关键词
erector spinae muscle; early non-small cell lung cancer; postoperative prognosis; sarcopenia; PROGNOSTIC NUTRITIONAL INDEX; SARCOPENIA; RISK; CLASSIFICATION; DIAGNOSIS; EXERCISE; OUTCOMES; SURGERY; DEATH;
D O I
10.1093/ejcts/ezac510
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: Erector spinae muscle (ESM) is an antigravity muscle group that can be evaluated as an index of muscle loss on chest computed tomography. The amount of ESM has been reported to be related to the prognosis of several respiratory diseases. However, few studies clarify the impact on postoperative non-small-cell lung cancer (NSCLC). We investigated the relationship between ESM and postoperative prognosis in patients with early-stage NSCLC.METHODS: We reviewed the medical records of 534 patients with stage I NSCLC who underwent lobectomy or segmentectomy. The ESM was identified by preoperative computed tomography, and the amount was normalized according to height and sex. Overall survival, lung cancer-related deaths and non-lung cancer-related deaths (NLCRD) were analysed using log-rank and Gray's tests. Multivariable analyses were conducted to identify factors that influenced overall survival (OS) and NLCRD.RESULTS: The amount of ESM normalized according to height and sex was significantly associated with age and body mass index. When the amount was low, OS (5-year OS, 79.6 vs 89.5%; P < 0.001) and NLCRD (5-year cumulative mortality rate, 14.7 vs 6.8%; P < 0.001) were significantly worse, although no difference was found in lung cancer-related deaths.CONCLUSIONS: The amount of preoperative ESM was strongly related to non-lung cancer-related death and was a significant prognostic factor for stage I NSCLC. Patients with a low amount of the muscle should be treated based on proper risk assessment.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Is routine preoperative mediastinoscopy indicated in clinical stage I non-small-cell lung cancer?
    Pramesh, CS
    Mistry, RC
    Deshpande, RK
    Sharma, S
    ANNALS OF THORACIC SURGERY, 2004, 77 (05): : 1877 - 1878
  • [2] Phase II Study of Preoperative Gefitinib in Clinical Stage I Non-Small-Cell Lung Cancer
    Lara-Guerra, Humberto
    Waddell, Thomas K.
    Salvarrey, Maria A.
    Joshua, Anthony M.
    Chung, Catherine T.
    Paul, Narinder
    Boerner, Scott
    Sakurada, Akira
    Ludkovski, Olga
    Ma, Clement
    Squire, Jeremy
    Liu, Geoffrey
    Shepherd, Frances A.
    Tsao, Ming-Sound
    Leighl, Natasha B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6229 - 6236
  • [3] Tailored Therapy for Stage I Non-Small-Cell Lung Cancer
    Ng, Calvin S. H.
    Zhao, Ze-Rui
    Lau, Rainbow W. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (03) : 268 - +
  • [4] Preoperative chemotherapy for non-small-cell lung cancer
    Hanna, Gerard G.
    Siva, Shankar
    Plumridge, Nikki
    Solomon, Benjamin
    Ball, David L.
    LANCET, 2014, 384 (9939): : 232 - 233
  • [5] The impact of coexisting lung diseases on outcomes in patients with pathological Stage I non-small-cell lung cancer
    Tao, Hiroyuki
    Onoda, Hideko
    Okabe, Kazunori
    Matsumoto, Tsuneo
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2018, 26 (06) : 1009 - 1015
  • [6] Novel treatment options in stage I non-small-cell lung cancer
    Tarasevych, Svitlana
    Lauwers, Patrick
    Vandaele, Frederik
    van Meerbeeck, Jan P.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (09) : 1007 - 1020
  • [7] PROTON BEAM THERAPY FOR STAGE I NON-SMALL-CELL LUNG CANCER
    Makita, Chiyoko
    Nakamura, Tatsuya
    Inokuchi, Haruo
    Tomoda, Takuya
    Takada, Akinori
    Takayama, Kanako
    Shiomi, Miho
    Kato, Takahiro
    Fuwa, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S504 - S505
  • [8] Estimating the Impact of Extended Delay to Surgery for Stage I Non-small-cell Lung Cancer on Survival
    Mayne, Nicholas R.
    Elser, Holly C.
    Darling, Alice J.
    Raman, Vignesh
    Liou, Douglas Z.
    Colson, Yolonda L.
    D'Amico, Thomas A.
    Yang, Chi-Fu Jeffrey
    ANNALS OF SURGERY, 2021, 273 (05) : 850 - 857
  • [9] The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer
    Ambrogi, V
    Pompeo, E
    Elia, S
    Pistolese, GR
    Mineo, TC
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2003, 23 (05) : 811 - 817
  • [10] Preoperative inductive chemotherapy in non-small-cell lung cancer
    Manegold, C
    ONKOLOGIE, 1996, 19 (01): : 82 - 82